Breaking News, Trials & Filings

FDA Approves Roche’s Tecentriq Combo for Melanoma

Tecentriq with Cotellic and Zelboraf helped people live longer without disease worsening or death compared to placebo.

By: Contract Pharma

Contract Pharma Staff

The FDA has approved Roche’s Tecentriq (atezolizumab) plus Cotellic (cobimetinib) and Zelboraf (vemurafenib) for the treatment of BRAF V600 mutation-positive advanced melanoma patients.  The safety profile observed in the Tecentriq combination was consistent with the known safety profiles of the individual medicines.

 The supplemental Biologics License Application (sBLA) for Tecentriq was granted under priority review. The approval is based on results from the Phase III IMspire150 study, in...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters